Research at MD Anderson
Scroll Ahead
Research fuels our mission to end cancer
Many of the greatest minds in cancer research are at MD Anderson. They're here because MD Anderson offers a unique environment that accelerates their ability to end cancer. They collaborate with other cancer experts – in different research areas and with the world's leading cancer doctors. Bright students and trainees contribute further to our dynamic research environment. Discoveries are fueled by vast research support and resources. Tomorrow's medicine is available to our patients first since we have the most cancer clinical trials in the world. These research efforts work in parallel to fight cancer through prevention, early diagnosis, effective therapies and scientific breakthroughs.
Learn more about our research areas
Find out how collaboration drives our mission to end cancer
2018 Research Publication Stats
3,540
peer-reviewed articles
100
scientific editorials
560
research reviews
Our researchers and physician-scientists are remarkably productive. With over 4,000 research articles, editorials and reviews published in 2018, their research efforts solidify MD Anderson's status as one of the nation's top comprehensive cancer centers.
Departments, Labs and Institutes
MD Anderson has many parts, including departments, labs and institutes, but the sum of those parts is ending cancer. MD Anderson's reach is comprehensive when it comes to eliminating cancer.
Research Areas
Since 1941, MD Anderson has been home to some of the brightest minds across a variety of cancer research areas.
Resources
MD Anderson provides research tools and resources to fuel the discoveries of our scientists.
Moon Shots Program
Inspired by an unprecedented era of scientific discovery a generation ago, the Moon Shots Program™ was launched by MD Anderson as an ambitious plan to make a giant leap in cancer research to benefit patients.
Learn more about the Moon Shots ProgramResearch Highlights
Immunotherapy research
Lung cancer screening
Glioblastoma research
MRI-guided radiation
Immunotherapy alliance
PARP inhibitors
Biomarker research
Precision medicine
CANCER FRONTLINE
Targeting T-cell lymphoma using CAR-modified cells
A Dream Team assembled by Stand Up To Cancer will receive $8 million in funding to explore ways to better treat T-cell lymphoma, a type of blood cancer. Investigators from MD Anderson are researching the use of CAR-modified natural killer (NK) cells, which can be generated from umbilical cord blood.
HPV-Related Oropharyngeal Cancers
New biomarker may help lower treatment intensity, reduce side effects for certain patients